Ieramilimab Biosimilar - Research Grade

Human

LAG3

>1mg/ml

Human IgG4 (S228P)-Kappa

Anti-Mouse LAG-3 (C9B7W) In Vivo Antibody - Low Endotoxin (ICH1078), TSR-033 Biosimilar - Research Grade (ICH5067), Relatlimab Biosimilar - Research Grade (ICH5117), Miptenalimab Biosimilar - Research Grade (ICH5259), Encelimab Biosimilar - Research Grade (ICH5524), Favezelimab Biosimilar - Research Grade (ICH5545), Fianlimab Biosimilar - Research Grade (ICH5548), Negalstobart Biosimilar - Research Grade (ICH5704), Tuparstobart Biosimilar - Research Grade (ICH5948)

https://www.imgt.org/mAb-DB/

ICH3002

P18627

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ieramilimab, an anti-LAG3 antibody, supplied for research use only. It is built around the human LAG3 (lymphocyte-activation gene 3, CD223; UniProt P18627) target as a human IgG4 (S228P)-kappa immunoglobulin, and is not the clinical drug or intended for human or veterinary use. The stabilized S228P hinge mutation limits IgG4 Fab-arm exchange, giving a consistent monovalent-per-arm binding reagent. It is useful as a target-specific tool for characterizing LAG3 biology and checkpoint pathways in vitro: as a capture or detection reagent in ELISA and biolayer/SPR binding assays, for flow-cytometric staining of LAG3-expressing cells, as a blocking reagent in functional co-culture experiments, as an isotype-matched positive control alongside other IgG4 checkpoint biosimilars, and as a benchmarking standard in bioassay development. Material is offered at research grade with low endotoxin (typically <1 EU/mg; ultra-low <0.5 EU/mg options), and in bulk milligram-to-gram quantities suitable for assay standardization and preclinical screening workflows. LAG3 (lymphocyte-activation gene 3; CD223; UniProt P18627) is a type I transmembrane protein structurally related to CD4, expressed on activated CD4+ and CD8+ T cells, regulatory T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. It functions as an inhibitory immune checkpoint receptor that dampens T-cell proliferation, activation, and effector cytokine output, and contributes to regulatory T-cell suppressive function. Its principal ligand is MHC class II, to which it binds with higher affinity than CD4; additional reported ligands include the liver-secreted protein FGL1, galectin-3, and LSECtin. Sustained LAG3 expression is a hallmark of T-cell exhaustion in chronic infection and tumors, frequently co-expressed with PD-1, making it a prominent co-inhibitory target for combination checkpoint modulation.

Lymphocyte activation gene 3 protein, FDC

Detects human LAG3

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Ieramilimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Ieramilimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ieramilimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ieramilimab that binds human LAG3.